XML 141 R128.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
Dec. 31, 2022
USD ($)
Other commitments  
Capital expenditures $ 42,000,000
Milestone payments in terms of collaboration and license agreements, aggregate 250,000,000
Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc.  
Other commitments  
Milestone payments in terms of collaboration and license agreements, aggregate 35,000,000
Mitsubishi Tanabe Pharma Corporation  
Other commitments  
Milestone payments in terms of collaboration and license agreements, aggregate 60,000,000
Novaliq GmbH  
Other commitments  
Milestone payments in terms of collaboration and license agreements, aggregate 48,000,000
Eyenovia, Inc.  
Other commitments  
Milestone payments in terms of collaboration and license agreements, aggregate $ 35,000,000